HomeKRONOX › Filing
🔔 Get instant alerts when KRONOX files quarterly results on BSE Start free trial →

Announcement of SPA executed by Promoter with Indo Borax & Chemicals Limited (Acquirer)and Zenrock Chemicals Privated Limited (PAC)

Filed: 20 Aug 2026, 13:06 IST Exchange: BSE Category: Merger/Acquisition — Share Purchase Agreement
SPA executed by promoters to sell 64.26% stake to Indo Borax & Chemicals Ltd - Sellers: 3 promoters holding 74.21% total, selling 64.26% to Acquirer - SPA price: Rs 103.22/share; effective price Rs 105.87/share including consultancy fees - Completion subject to conditions; triggers mandatory open offer under SEBI Takeover Regulations - Post-transaction, Acquirer becomes promoter; Sellers reclassified as public - Sellers to resign from board; Acquirer to appoint 3 nominee directors - Sellers' remaining 9.95% shares locked-in; Acquirer has right of first refusal - Sellers to provide consultancy post-transaction - Restrictions on Sellers' voting rights until completion - Transaction is arm's length, no related party involvement
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 KRONOX — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add KRONOX to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Kronox Lab Sciences Limited

Important. The summary above is generated automatically from Kronox Lab Sciences Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.